The global impact and cost-effectiveness of a melioidosis vaccine
Tóm tắt
Từ khóa
Tài liệu tham khảo
Cheng A, Currie B. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev. 2005;18(2):383–416.
Limmathurotsakul D, Golding N, Dance DAB, Messina JP Pigott DM, Moyes CL, et al. Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis. Nat Microbiol. 2016;1(Jan):1–5.
Limmathurotsakul D, Wongratanacheewin S, Teerawattanasook N, Wongsuwan G, Chaisuksant S, Chetchotisakd P, et al. Increasing incidence of human melioidosis in Northeast Thailand. Am J Trop Med Hyg. 2010;82(6):1113–7.
Parameswaran U, Baird RW, Ward LM, Currie BJ. Melioidosis at royal Darwin hospital in the big 2009-2010 wet season: comparison with the preceding 20 years. Med J Aust. 2012;196(5):345–8.
Wuthiekanun V, Peacock SJ. Management of melioidosis. Expert Rev of Anti Infect Ther. 2006;4(3):445–55.
Peacock SJ, Limmathurotsakul D, Lubell Y, Koh GCKW, White LJ, Day NPJ, et al. Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes. PLoS Negl Trop Dis. 2012;6(1):1–8.
Titball RW, Burtnick MN, Bancroft GJ, Brett P. Burkholderia pseudomallei and Burkholderia mallei vaccines: are we close to clinical trials? Vaccine. 2017;35(44):5981–9.
Inglis TJJ, Sousa AQ. The public health implications of melioidosis. Braz J Infect Dis. 2009;13(1):59–66.
Lipsitz R, Garges S, Aurigemma R, Baccam P, Blaney DD, Cheng AC, et al. Workshop on treatment of and Postexposure prophylaxis for Burkholderia pseudomallei and B. mallei infection, 2010. Emerg Infect Dis. 2012;18(12):1–11.
Bognar G. Does cost effectiveness analysis unfairly discriminate against people with disabilities? J Appl Philos. 2010;27(4):394–408.
Ketheesan N. Melioidosis: a century of observation and research. The Netherlands: Elsevier; 2012.
Population Division, United Nations. Country specific age distribution-World population prospects: 2015, UN.
Hanna JN, Humphreys JL, Brookes DL, Messina T, Raulli A. Melioidosis in North Queensland, 2000-2009. Commun Dis Intell Q Rep. 2010;34(4):444–7.
Currie BJ, Ward L, Cheng AC. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis. 2010;4(11):e900.
Vlieghe E, Kruy L, De Smet B, Kham C, Veng CH, Phe T, et al. Melioidosis, phnom penh, Cambodia. Emerg Infect Dis. 2011;17(7):1289–92.
Chou DW, Chung KM, Chen CH, Cheung BM. Bacteremic melioidosis in southern Taiwan: clinical characteristics and outcome. J Formos Med Assoc. 2007;106(12):1013–22.
Mohd Roslani AD, Tay ST, Puthucheary SD, Rukumani DV, report SICS. Predictors of severe disease in melioidosis patients in Kuala Lumpur, Malaysia. Am J Trop Med Hyg. 2014;91(6):1176–8.
Deris ZZ, Hasan H, Siti Suraiya MN. Clinical characteristics and outcomes of bacteraemic melioidosis in a teaching hospital in a northeastern state of Malaysia: a five-year review. J Infect Dev Ctries. 2010;4(7):430–5.
Hassan MR, Pani SP, Peng NP, Voralu K, Vijayalakshmi N, Mehanderkar R, et al. Incidence, risk factors and clinical epidemiology of melioidosis: a complex socio-ecological emerging infectious disease in the Alor Setar region of Kedah, Malaysia. BMC Infect Dis. 2010;10:302.
Lo TJ, Ang LW, James L, Goh KT. Melioidosis in a tropical city state, Singapore. Emerg Infect Dis. 2009;15(10):1645–7.
Phuong DM, Trung TT, Breitbach K, Tuen NQ, Nubel U, Flunker G, et al. Clinical and microbiological features of melioidosis in northern Vietnam. Trans R Soc Trop Med Hyg. 2008;102(Suppl 1):S30–6.
WHO. Global Health Observatory Data Repository. Geneva: Mortality and burden of disease (Life table), World Health Organization; 2015. [Data file] Retrieved from http://apps.who.int/gho/data/node.main.LIFECOUNTRY?lang=en .
Census and Statistics Department, Hong Kong Special Administrative Region. Hong Kong Life Table 2017, Census and Statistics Department, the Government of the Hong Kong Special Administrative Region. [Data file] Retrieved from http://www.censtatd.gov.hk/hkstat/sub/sp190.jsp?productCode=B1120016 .
The International Diabetes Federation (IDF). International Diabetes Federation Diabetes Atlas 5th edn. Country summary table:estimate for 2012. 2013.
Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. PLoS One. 2016;11(7):1–18.
Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health. 2014;2(7):e406–14.
Kimman M, Vathesatogkit P, Woodward M. Validity of the Thai EQ-5D in an occupational population in Thailand; 2013. p. 1499–506.
Kulpeng W, Sornsrivichai V, Chongsuvivatwong V, Rattanavipapong W, Leelahavarong P, Cairns J, et al. Variation of health-related quality of life assessed by caregivers and patients affected by severe childhood infections. BMC Pediatr. 2013;13(1):1.
WHO Commission on Macroeconomic and Health. Macroeconomics and health: investing in health for economic development. Geneva: World Health Organization; 2001.
WHO-CHOICE unit cost estimates for service delivery, The World Health Organisation (WHO). 2011. [online] Available at: http://www.who.int/choice/cost-effectiveness/inputs/health_service/en/
Drug Medical Supply and Information Center (DMSIC), Ministry of Public Health Thailand [online]. Available at: http://dmsic.moph.go.th/dmsic/force_down.php?f_id=716 . Accessed 17 Aug 2017.
Drug Tariff (2017), National Health Services (NHS) UK. [online] Available at: https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff . Accessed 17 Aug 2017.
Majoni SW, Hughes JT, Heron B, Currie BJ. Trimethoprim+sulfamethoxazole reduces rates of melioidosis in high-risk hemodialysis patients. Kidney Int Rep. 2017;3(1):160–7.
Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in countries : a novel approach and evidence from cross-country data. BMJ Glob Health. 2018;3:e000964.